Benztropine Mesylate Injection
NDC 68475-512
Product Information
Benztropine Mesylate is a ANDA-approved product labeled by Navinta Llc. Benztropine is used to treat symptoms of Parkinson's disease or involuntary movements due to the side effects of certain psychiatric drugs (antipsychotics such as chlorpromazine/haloperidol). It is supplied as a injection for intramuscular; intravenous administration. This product entry covers the primary NDC 68475-512 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Intravenous - Administration within or into a vein or veins.
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 68475-512?
What are the uses of this product?
What are Active Ingredients of this product?
- BENZTROPINE MESYLATE 1 mg/mL - A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- BENZTROPINE MESYLATE (UNII: WMJ8TL7510)
- BENZTROPINE (UNII: 1NHL2J4X8K) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 885205 - benztropine mesylate 2 MG in 2 ML Injection
- RxCUI: 885205 - 2 ML benztropine mesylate 1 MG/ML Injection
- RxCUI: 885205 - benztropine mesylate 2 MG per 2 ML Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.